Researchers are looking to further our knowledge on disease biology and treatment selection for gastroesophageal adenocarcinoma. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients for the future.
Patients with suspected or histologically confirmed localized gastroesophageal adenocarcinoma amenable to curative intent therapy with surgery as standard of care, either with or without induction chemotherapy or chemo radiotherapy.
Age ≥18 years.
Eastern Cooperative Group (ECOG) performance status 0-2
Patients must have a histological or radiological diagnosis of advanced gastroesophageal cancer.
Patients who are planned for definitive chemoradiation without surgical resection will be excluded from this study.
Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
Patients with one or more contraindications to tumour biopsy according to UHN's standard biopsy procedures.
Patients who had prior systemic treatment for advanced or metastatic gastroesophageal cancer.